

Date and Time: 1 July 2014, 10:00 – 16:00

Minutes: Confirmed

Guideline Development Group Meeting

15

Place: Boardroom, NCGC, 180 Great Portland Street, London W1W 5QZ

Present: Abdallah Al-Mohammad, Consultant Cardiologist & Honorary Senior Clinical Lecturer
Jane Butler, Heart Failure Consultant Nurse
Saskia Cheyne, Project Manager, NCGC
Martin Cowie, Professor of Cardiology
Katharina Dworzynski, Senior Research Fellow, NCGC
Edward Griffin, Health Economist, NCGC
Suzanna Hardmann, Consultant Cardiologist
Nicholas Ioannou, Consultant in Critical Care & Anaesthesia
Jason Kendall, Consultant in Emergency Medicine
Andrew Ludman, Specialist Trainee Adviser
Jonathan Mant, GDG Chair, Professor of Primary Care Research
Jayne Masters, Lead Heart Failure Specialist Nurse
Su Park, Research Fellow, NCGC
Tanzeem Raza, Consultant Physician in Acute Medicine
Gill Ritchie, Operations Director, NCGC
David Wonderling, Head of Health Economics, NCGC
Giulia Zuodar, Document Editor, NCGC

Apologies:

Peter Bolton, Patient member
Edgar Masanga, Costing Lead, NICE
John McMurray, Professor of Medical Cardiology

Observers:

Catherine Will, Senior Lecturer, School of Law, Politics and Sociology, University of Sussex

In attendance:

NICE Staff:		
NICE attendee 1	Caroline Keir	Guidelines Commissioning Manager
NICE attendee 2	Annette Mead	Senior Medical Editor
NICE attendee 3	Carmel Thomason	Implementation Adviser

Notes

1. **Welcome and declarations of interest**

The Chair welcomed the group to the fifteenth and last meeting of this GDG. The Chair asked all GDG members to declare any relevant conflicts of interest. AAM declared attending the European Heart Failure and International congress on acute heart failure in Athens in May 2014, invited by Servier. This was classified as a personal pecuniary interest. The Chair agreed that he should declare and participate. AAM declared being the principal investigator in Sheffield for the Live: Life study of the over 70 year old patients with CHF being treated with ivabradine and having their symptoms, quality of life and progress assessed; he is co-investigator on REVIVED, a study of the role of percutaneous coronary intervention in patients with CHF and significant coronary artery disease; and he is also principal investigator in Sheffield and member of the steering committee on the SILHF trial of sildenafil in patients with HF-LVSD and mild pulmonary hypertension; principal investigator in Sheffield for the Serelaxin in acute heart failure trial. These were classified as personal non-pecuniary interests and the Chair agreed that he should declare and participate.

MC declared receiving honoraria for chairing or attending Advisory Boards for Novartis, Bayer, ResMed, Boston Scientific. He also declared receiving honoraria for travelling to lecture for Bayer, Servier, St Jude Medical, CadioMEMS, Pfizer/BMS, Novartis, ResMed. These were classified as personal pecuniary interests. The Chair agreed that he should declare and participate. MC also declared receiving a research grant from Bayer to Imperial College to support research in atrial fibrillation in chronic heart failure. This was classified as a non-personal pecuniary interest and the Chair agreed that he should declare and participate. Finally, MC declared being the Chair of the Consensus Group of the NICE Implementation Collaborative on the use of novel oral anticoagulants (report published 18 June 2014), and advisor to NICE on the patient decision aid for the updated AF guidance, issued on 18 June 2014; he is also a member of the Stroke in AF Initiative, funded by ABPI, with parliamentary launch meeting of NOAC report, April 2014. These were classified as personal non-pecuniary interests and the Chair agreed that he should declare and participate.

JK declared being North Bristol NHS Trust local principle investigator for Seralexin heart failure trial due to start later in 2014 (trial sponsored by Novartis Pharmaceuticals). This was classified as a personal non-pecuniary interest and the Chair agreed that he should declare and participate.

AL declared receiving an educational grant for part of the costs to attend the British Cardiac Society 2014 from Servier - £270. This was classified as a personal pecuniary interest and no further action was required.

2. **Agree GDG14 minutes**

The minutes of the last meeting of this group were agreed as a true and accurate account of the meeting.

3. **Comments from stakeholders and invited peer reviewers**

Notes

The GDG reviewed comments from stakeholders and invited peer reviewers on the consultation draft of the guideline and agreed responses to the comments and actions to be taken.

4. **NICE Implementation and costing team**

The NICE implementation team discussed with the GDG the main changes in current practice introduced by the guideline.

5. **Health economic feedback**

EG and DW updated the GDG on the health economic model, following stakeholders' comments.

6. **Any other business**

None.